Estudo randomizado | Ibrutinibe-venetoclax com duração fixa em pacientes com leucemia linfocítica crônica e comorbidades.
17 Mai, 2022 | 11:48h
Comentário no Twitter
In older patients and/or those with comorbidities with untreated #CLL, treatment with ibrutinib-venetoclax was superior to chlorambucil-obinutuzumab, with fewer events and longer PFS after just over 2 yrs of follow-up. Read about the GLOW trial: https://t.co/gYjksIhp96
#LeuSM pic.twitter.com/aBnpdeKhFO— NEJM Evidence (@NEJMEvidence) May 13, 2022